{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:40:15Z","timestamp":1784133615706,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H02757"],"award-info":[{"award-number":["18H02757"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00259-021-05544-4","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T07:04:12Z","timestamp":1630479852000},"page":"821-833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Eribulin improves tumor oxygenation demonstrated by 18F-DiFA hypoxia imaging, leading to radio-sensitization in human cancer xenograft models"],"prefix":"10.1007","volume":"49","author":[{"given":"Tomoki","family":"Bo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6757-1110","authenticated-orcid":false,"given":"Hironobu","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2532-9916","authenticated-orcid":false,"given":"Yuki","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-9422","authenticated-orcid":false,"given":"Motofumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Higashikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-3918","authenticated-orcid":false,"given":"Osamu","family":"Inanami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0483-9706","authenticated-orcid":false,"given":"Yuji","family":"Kuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"5544_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"5544_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE Desantis","year":"2019","unstructured":"Desantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438\u201351.","journal-title":"CA Cancer J Clin"},{"key":"5544_CR3","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1007\/s00018-007-7390-6","volume":"64","author":"K Lundgren","year":"2007","unstructured":"Lundgren K, Holm C, Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cell Mol Life Sci. 2007;64:3233\u201347.","journal-title":"Cell Mol Life Sci"},{"key":"5544_CR4","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1021\/nn405773r","volume":"8","author":"P Prasad","year":"2014","unstructured":"Prasad P, Gordijo CR, Abbasi AZ, Maeda A, Ip A, Rauth AM, et al. Multifunctional albumin-MnO2 nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response. ACS Nano. 2014;8:3202\u201312.","journal-title":"ACS Nano"},{"key":"5544_CR5","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.1021\/ja00302a042","volume":"107","author":"D Uemura","year":"1985","unstructured":"Uemura D, Takahashi K, Yamamoto T, Katayama C, Tanaka J, Okumura Y, et al. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J Am Chem Soc. 1985;107:4796\u20138.","journal-title":"J Am Chem Soc"},{"key":"5544_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/0008-5472.CAN-10-1874","volume":"71","author":"MJ Towle","year":"2011","unstructured":"Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011;71:496\u2013505.","journal-title":"Cancer Res"},{"key":"5544_CR7","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","volume":"64","author":"G Kuznetsov","year":"2004","unstructured":"Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin b macrocyclic ketone analog E7389. Cancer Res. 2004;64:5760\u20136.","journal-title":"Cancer Res"},{"key":"5544_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","volume":"81","author":"U Swami","year":"2012","unstructured":"Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin\u2014a review of preclinical and clinical studies. Crit Rev Oncol Hematol. 2012;81:163\u201384.","journal-title":"Crit Rev Oncol Hematol"},{"key":"5544_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914\u201323.","journal-title":"Lancet"},{"key":"5544_CR10","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-11-2149","volume":"18","author":"M Donoghue","year":"2012","unstructured":"Donoghue M, Lemery SJ, Yuan W, He K, Sridhara R, Shord S, et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a \u201cPhysician\u2019s Choice\u201d control arm in a randomized approval trial. Clin Cancer Res. 2012;18:1496\u2013505.","journal-title":"Clin Cancer Res"},{"key":"5544_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7150\/jca.8748","volume":"5","author":"T Gamucci","year":"2014","unstructured":"Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, et al. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. J Cancer. 2014;5:320\u20137.","journal-title":"J Cancer"},{"key":"5544_CR12","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Sch\u00f6ffski","year":"2016","unstructured":"Sch\u00f6ffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387:1629\u201337.","journal-title":"Lancet"},{"key":"5544_CR13","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-11-3075","volume":"18","author":"E Pean","year":"2012","unstructured":"Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, et al. The European Medicines Agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res. 2012;18:4491\u20137.","journal-title":"Clin Cancer Res"},{"key":"5544_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-019-0521-x","volume":"9","author":"S Zhao","year":"2019","unstructured":"Zhao S, Yu W, Ukon N, Tan C, Nishijima K-I, Shimizu Y, et al. Elimination of tumor hypoxia by eribulin demonstrated by 18F-FMISO hypoxia imaging in human tumor xenograft models. EJNMMI Res. 2019;9:1\u201310.","journal-title":"EJNMMI Res"},{"key":"5544_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/bjc.2016.122","volume":"114","author":"S Ueda","year":"2016","unstructured":"Ueda S, Saeki T, Takeuchi H, Shigekawa T, Yamane T, Kuji I, et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer. 2016;114:1212\u20138.","journal-title":"Br J Cancer"},{"key":"5544_CR16","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial\u2013mesenchymal transition (EMT) to mesenchymal\u2013epithelial transition (MET) states. Br J Cancer. 2014;110:1497\u2013505.","journal-title":"Br J Cancer"},{"key":"5544_CR17","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1093\/annonc\/mdu174","volume":"25","author":"TS Mok","year":"2014","unstructured":"Mok TS, Geater SL, Iannotti N, Thongprasert S, Spira A, Smith D, et al. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. Ann Oncol. 2014;25:1578\u201384.","journal-title":"Ann Oncol"},{"key":"5544_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-018-1086-8","volume":"21","author":"JS Lee","year":"2019","unstructured":"Lee JS, Yost SE, Blanchard S, Schmolze D, Yin HH, Pillai R, et al. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21:1\u20133.","journal-title":"Breast Cancer Res"},{"key":"5544_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105:1334\u201342.","journal-title":"Cancer Sci"},{"key":"5544_CR20","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1111\/cas.13637","volume":"109","author":"S Miki","year":"2018","unstructured":"Miki S, Imamichi S, Fujimori H, Tomiyama A, Fujimoto K, Satomi K, et al. Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma. Cancer Sci. 2018;109:2275\u201385.","journal-title":"Cancer Sci"},{"key":"5544_CR21","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00259-008-0772-7","volume":"35","author":"EGC Troost","year":"2008","unstructured":"Troost EGC, Laverman P, Philippens MEP, Lok J, Van Der Kogel AJ, Oyen WJG, et al. Correlation of [18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging. 2008;35:1803\u201311.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5544_CR22","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s00259-017-3754-9","volume":"44","author":"T Toyonaga","year":"2017","unstructured":"Toyonaga T, Hirata K, Shiga T, Nagara T. Players of \u2018hypoxia orchestra\u2019 \u2013 what is the role of FMISO? Eur J Nucl Med Mol Imaging. 2017;44:1679\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5544_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF03164868","volume":"13","author":"J-K Chung","year":"1999","unstructured":"Chung J-K, Chang YS, Lee YJ, Kim YJ, Jeong JM, Lee DS, et al. The effect of tumor size on F-18-labeled fluorodeoxyglucose and fluoroerythronitroimidazole uptake in a murine sarcoma model. Ann Nucl Med. 1999;13:303\u20138.","journal-title":"Ann Nucl Med"},{"key":"5544_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.nucmedbio.2019.01.008","volume":"70","author":"N Nakata","year":"2019","unstructured":"Nakata N, Kiriu M, Okumura Y, Zhao S, Nishijima K, Shiga T, et al. Comparative evaluation of [18F]DiFA and its analogs as novel hypoxia positron emission tomography and [18F]FMISO as the standard. Nucl Med Biol. 2019;70:39\u201345.","journal-title":"Nucl Med Biol"},{"key":"5544_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11307-018-1214-y","volume":"21","author":"Y Shimizu","year":"2019","unstructured":"Shimizu Y, Zhao S, Yasui H, Nishijima K-I, Matsumoto H, Shiga T, et al. A novel PET probe \u201c[18F]DiFA\u201d accumulates in hypoxic region via glutathione conjugation following reductive metabolism. Mol Imaging Biol. 2019;21:122\u20139.","journal-title":"Mol Imaging Biol"},{"key":"5544_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-018-0470-9","volume":"9","author":"S Watanabe","year":"2019","unstructured":"Watanabe S, Shiga T, Hirata K, Magota K, Okamoto S, Toyonaga T, et al. Biodistribution and radiation dosimetry of the novel hypoxia PET probe [18F]DiFA and comparison with [18F]FMISO. EJNMMI Res. 2019;9:1\u201311.","journal-title":"EJNMMI Res"},{"key":"5544_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-016-0246-z","volume":"6","author":"N Ukon","year":"2016","unstructured":"Ukon N, Zhao S, Yu W, Shimizu Y, Nishijima K-I, Kubo N, et al. Dynamic PET evaluation of elevated FLT level after sorafenib treatment in mice bearing human renal cell carcinoma xenograft. EJNMMI Res. 2016;6:1\u20138.","journal-title":"EJNMMI Res"},{"key":"5544_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393\u2013410.","journal-title":"Nat Rev Cancer"},{"key":"5544_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","volume":"26","author":"P Vaupel","year":"2007","unstructured":"Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225\u201339.","journal-title":"Cancer Metastasis Rev"},{"key":"5544_CR30","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2012.171","volume":"9","author":"MR Horsman","year":"2012","unstructured":"Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9:674\u201387.","journal-title":"Nat Rev Clin Oncol"},{"key":"5544_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/bjc.2014.610","volume":"112","author":"IN Fleming","year":"2015","unstructured":"Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, Domarkas J, Lord S, Baldry C, Gilbert FJ. Imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2015;112:238\u201350.","journal-title":"Br J Cancer"},{"key":"5544_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11307-016-0994-1","volume":"19","author":"AG Sorace","year":"2017","unstructured":"Sorace AG, Syed AK, Barnes SL, Quarles CC, Sanchez V, Kang H, Yankeelov TE. Quantitative [18F]FMISO PET imaging shows reduction of hypoxia following trastuzumab in a murine model of HER2+ breast cancer. Mol Imaging Biol. 2017;19:130\u20137.","journal-title":"Mol Imaging Biol"},{"key":"5544_CR33","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/cas.13392","volume":"108","author":"K Ito","year":"2017","unstructured":"Ito K, Hamamichi S, Abe T, Akagi T, Shirota H, Kawano S, Asano M, Asano O, Yokoi A, Matsui J, Umeda IO, Fujii H. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models. Cancer Sci. 2017;108:2273\u201380.","journal-title":"Cancer Sci"},{"key":"5544_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0167-8140(96)91811-3","volume":"41","author":"M Nordsmark","year":"1996","unstructured":"Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41:31\u20139.","journal-title":"Radiother Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05544-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05544-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05544-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T12:05:51Z","timestamp":1643630751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05544-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5544"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05544-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"12 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Laboratory Animal Care and Use Committee of Hokkaido University and performed in accordance with the Guidelines for Animal Experiments at the Graduate School of Medicine, Hokkaido University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors have read the paper and provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}